BSE filing, NSE: CREDITACC. Summary written from the filing by ALFA Finder's alert engine.
CreditAccess Grameen Ltd: key numbers
- Share price
- ₹1,022.20
- Market cap
- ₹16,412 Cr
- Revenue (annual)
- ₹6,059 Cr
- Net profit (annual)
- ₹777.6 Cr
- P/E (TTM)
- 10.3×Sector 19.7×
- Promoter holding
- 63.83%-2.38% QoQ
- FII holding
- 14.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from CreditAccess Grameen Ltd
All →CreditAccess Grameen Earnings Call Transcript: Key Takeaways
CA Grameen reported record profits despite localized climate stress in Maharashtra and MP.
- Call
- Guides 25% growth
CreditAccess Grameen Management Change
CreditAccess Grameen Limited has appointed M/s. Sharp & Tannan as Statutory Auditor for a term of 36 months, effective July 1, 2027.
CreditAccess Grameen Other Announcement
CreditAccess Grameen filed its statement of utilization of issue proceeds for non-convertible securities for the quarter ended September 30, 2026, per SEBI LODR regulations.
CreditAccess Grameen Results Update
CreditAccess Grameen announced its Q2 FY27 financial results, reporting strong growth in profit and income, alongside positive business operational highlights for the quarter.
CreditAccess Grameen Investor Presentation: Key Takeaways
CreditAccess Grameen reported its highest quarterly profit of INR 502 Cr for Q2 FY27, crossing a major milestone with 19.5% YoY AUM growth driven by rural inclusive financing.
- Call
- Guides 25% growth
CreditAccess Grameen Q2 FY27 Results: Net Profit ₹501.6 Cr, Up 298.7% YoY
CreditAccess Grameen Ltd reported revenue from operations of ₹1,904 Cr (+26.2% YoY) and net profit of ₹501.6 Cr (+298.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹501.6 Cr · +298.7% YoY
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.